Short-Term Effects of Pecavaptan on Weight and Congestion in Acute Heart Failure
Authors:
- Daan C.H. CeelenDCDaan C.H. Ceelen
- Geert H.D. VoordesGVGeert H.D. Voordes
- Lucija CosicLCLucija Cosic
- Jozine M. ter MaatenJMJozine M. ter Maaten
- Steven R. GoldsmithSGSteven R. Goldsmith
- Daniel BurkhoffDBDaniel Burkhoff
- Finn GustafssonFGFinn Gustafsson
- Robert FrostRFRobert Frost
- Kevin DuarteKDKevin Duarte
- Luca MonzoLMLuca Monzo
- Nicolas GirerdNGNicolas Girerd
- Faiez ZannadFZFaiez Zannad
Open Access
- 22 July 2026
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 5 (7)
Abstract
No abstract availableFunding Information
- Pharmaceuticals Bayer
This publication has 26 references indexed in Scilit:
- Clinical Profiles and Prognostic Impact of Residual Intravascular and Tissue Congestion in Acute Heart FailureEuropean Journal of Heart Failure, 2025
- A Multicentre, Randomized, Double-Blind, Active and Placebo-Controlled Study of Pecavaptan, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Acute Heart Failure: The AVANTI TrialEuropean Journal of Heart Failure, 2025
- Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI TrialJournal of Cardiac Failure, 2021
- Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failureEuropean Journal of Heart Failure, 2020
- Basic concepts and practical equations on osmolality: Biochemical approachClinical Biochemistry, 2016
- Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal DysfunctionJournal of Cardiac Failure, 2016
- Renal Effects of Conivaptan, Furosemide, and the Combination in Patients With Chronic Heart FailureJournal of Cardiac Failure, 2011
- Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot StudyJournal of Cardiac Failure, 2008
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007
- Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart FailureA Randomized Controlled TrialJAMA, 2004